1. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD. (October 2017) Authors: Cahn, A.; Hamblin, J.N.; Begg, M.; Wilson, R.; Dunsire, L.; Sriskantharajah, S.; Montembault, M.; Leemereise, C.N.; Galinanes-Garcia, L.; Watz, H.; Kirsten, A.M.; Fuhr, R.; Hessel, E.M. Journal: Pulmonary pharmacology & therapeutics Issue: Volume 46(2017:Oct.) Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗